PEGASYS RBV SOLUTION Canada - English - Health Canada

pegasys rbv solution

hoffmann-la roche limited - peginterferon alfa-2a; ribavirin - solution - 180mcg; 200mg - peginterferon alfa-2a 180mcg; ribavirin 200mg - interferons

PEGASYS SOLUTION Canada - English - Health Canada

pegasys solution

pharmaand gmbh - peginterferon alfa-2a - solution - 180mcg - peginterferon alfa-2a 180mcg - interferons

PEGASYS SOLUTION Canada - English - Health Canada

pegasys solution

hoffmann-la roche limited - peginterferon alfa-2a - solution - 180mcg - peginterferon alfa-2a 180mcg - interferons

Pegasys RBV New Zealand - English - Medsafe (Medicines Safety Authority)

pegasys rbv

roche products (nz) ltd - peginterferon alfa-2a 270 µg/ml; ribavirin 200mg;  ;   - combination - 135µg/0.5ml + 200mg - active: peginterferon alfa-2a 270 µg/ml excipient: benzyl alcohol glacial acetic acid polysorbate 80 sodium acetate trihydrate sodium chloride water for injection active: ribavirin 200mg     excipient: ethylcellulose hypromellose as a component of opadry 03a14309 iron oxide red as a component of opadry 03a14309 iron oxide yellow as a component of opadry 03a14309 magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch purified talc as a component of opadry 03a14309 sodium starch glycolate titanium dioxide as a component of opadry 03a14309 triacetin - pegasys rbv is indicated for the treatment of chronic hepatitis c (chc) in: · non-cirrhotic patients · cirrhotic patients with compensated liver disease

Pegasys RBV New Zealand - English - Medsafe (Medicines Safety Authority)

pegasys rbv

roche products (nz) ltd - peginterferon alfa-2a 360 µg/ml; ribavirin 200mg;  ;   - combination - 180µg/0.5ml + 200mg - active: peginterferon alfa-2a 360 µg/ml excipient: benzyl alcohol glacial acetic acid polysorbate 80 sodium acetate trihydrate sodium chloride water for injection active: ribavirin 200mg     excipient: ethylcellulose hypromellose as a component of opadry 03a14309 iron oxide red as a component of opadry 03a14309 iron oxide yellow as a component of opadry 03a14309 magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch purified talc as a component of opadry 03a14309 sodium starch glycolate titanium dioxide as a component of opadry 03a14309 triacetin - pegasys rbv is indicated for the treatment of chronic hepatitis c (chc) in: · non-cirrhotic patients · cirrhotic patients with compensated liver disease

PEG-Intron CLEARCLICK Injector New Zealand - English - Medsafe (Medicines Safety Authority)

peg-intron clearclick injector

merck sharp & dohme (new zealand) limited - peginterferon alfa-2b 100ug - injection with diluent - 100 mcg - active: peginterferon alfa-2b 100ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose water for injection

DALFAMPRIDINE tablet, film coated, extended release United States - English - NLM (National Library of Medicine)

dalfampridine tablet, film coated, extended release

actavis pharma, inc. - dalfampridine (unii: bh3b64okl9) (dalfampridine - unii:bh3b64okl9) - dalfampridine extended-release tablets are indicated as a treatment to improve walking in adult patients with multiple sclerosis (ms). this was demonstrated by an increase in walking speed [see clinical studies (14)]. the use of dalfampridine is contraindicated in the following conditions: - history of seizure [see warnings and precautions (5.1)] - moderate or severe renal impairment (crcl ≤50 ml/min) [see warnings and precautions (5.2)] - history of hypersensitivity to dalfampridine or 4-aminopyridine; reactions have included anaphylaxis [see warnings and precautions (5.4)] risk summary there are no adequate data on the developmental risk associated with use of dalfampridine in pregnant women. administration of dalfampridine to animals during pregnancy and lactation resulted in decreased offspring viability and growth at clinically relevant doses [see data] . in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% an

REBETRON READY TO USE SOLUTION (ALBUMIN(HUMAN)FREE) (6000000 IU/ML AND 200MG CAPSULES) KIT Canada - English - Health Canada

rebetron ready to use solution (albumin(human)free) (6000000 iu/ml and 200mg capsules) kit

schering-plough canada inc - ribavirin; interferon alfa-2b - kit - 200mg; 6000000unit - ribavirin 200mg; interferon alfa-2b 6000000unit - interferons

REBETRON SOLUTION (ALBUMIN (HUMAN) FREE) (18 MIU MULTI-DOSE PEN / 200MG CAPSULES) KIT Canada - English - Health Canada

rebetron solution (albumin (human) free) (18 miu multi-dose pen / 200mg capsules) kit

schering-plough canada inc - ribavirin; interferon alfa-2b - kit - 200mg; 15000000unit - ribavirin 200mg; interferon alfa-2b 15000000unit - interferons

INTRON A INJ 3000000UNIT/VIAL LIQUID Canada - English - Health Canada

intron a inj 3000000unit/vial liquid

avondale (brinny) chemical company - interferon alfa-2b - liquid - 3000000unit - interferon alfa-2b 3000000unit - antineoplastic agents